The United States FDA inspection, conducted between September 9-20, concluded with the issuance of a Form 483, with zero observations. Shares of Glenmark Pharmaceuticals Ltd ended at ₹1,635, down by ₹16.15, or 0.98%, on the BSE.
The United States FDA inspection, conducted between September 9-20, concluded with the issuance of a Form 483, with zero observations. Shares of Glenmark Pharmaceuticals Ltd ended at ₹1,635, down by ₹16.15, or 0.98%, on the BSE.